Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Free-Cash-Flow-To-The-Firm" stands at 16.22 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025.
Sanofi SA's third quarter result of 3.93 Billion EUR for the item "Free Cash Flow To The Firm" represents an increase of 70.50 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 3.93 Billion EUR for the item "Free Cash Flow To The Firm" represents a decrease of -3.23 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 16.22 Billion EUR for the item "Free Cash Flow To The Firm" represents a decrease of -0.8 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 79.67 percent compared to the value the year prior.
The 1 year change in percent is 79.67.
The 3 year change in percent is 108.15.
The 5 year change in percent is 123.09.
The 10 year change in percent is 145.43.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Free Cash Flow To The Firm | 905,699,262,464.00 |
![]() | Johnson & Johnson - Free Cash Flow To The Firm | 486,508,953,600.00 |
![]() | AbbVie Inc - Free Cash Flow To The Firm | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To The Firm | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To The Firm | 280,205,508,085.11 |